Impact of antiphospholipid biology in maternal Down syndrome screening

Prenatal Diagnosis

Volumn 29, Issue 5, 2009, Pages 481-488

  Brochet, Christine ^a   Morin, Nathalie ^a,b   Coudert, Mathieu ^a   Vauthier Brouzes, Danièie ^a   Costedoat Chalumeau, Nathalie ^a   Bernard, Maguy ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Faculty of Medicine   (France)

Author keywords

Antiphospholipid antibodies; Prenatal screening; Risk calculation; Trisomy 21

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; PHOSPHOLIPID ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; PREGNANCY OUTCOME; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; TRISOMY 21; ANTIPHOSPHOLIPID SYNDROME; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; EVALUATION; METHODOLOGY; MOTHER; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; COHORT STUDIES; DOWN SYNDROME; FEMALE; HUMANS; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 66849122581     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2227     Document Type: Article

References (44)

1. Alkazaleh F, Chadda V, Viero S, et al. 2006. Second-trimester prediction of severe placental complications in women with combined elevations in alpha-foetoprotein and human chorionic gonadotrophin. Am J Obstet Gynecol 194: 821-827.
2. Anfuso S, Soncini E, Bonelli P, Piantelli G, Gramellini D. 2007. Second-trimester maternal serum alpha-fetoprotein elevation and its association with adverse maternal/fetal outcome: ten years experience. Acta Biomed Ateneo Parmense 78(3): 214-219.
3. Atanassova PA. 2007. Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview. Yonsei Med J 48(6): 901 -926.
4. Baschat AA, Harman CR, Farid G, Chodirker BN, Evans JA. 2002. Very low second-trimester maternal serum alpha-fetoprotein: Association with high birth weight. Obstet Gynecol 99(4): 531 -536.
5. Brownbill P, Edwards D, Jones C, et al. 1995. Mechanisms of alphafoetoprotein transfer in the perfused human placental cotyledon from uncomplicated pregnancy. J Clin Invest 96: 220-226.
6. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. 1988. Low second trimester serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 95: 330-333.
7. Canick JA, MacRae AR. 2005. Second trimester serum markers. Semin Perinatol 29: 203 -208. Chandra S, Scott H, Dodds L, Watts C, Blight C, Van den Hof M. 2003. Unexplained elevated serum alpha-foetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol 189: 775-781.
8. Clowse ME, Magder LS, Witter F, Petri M. 2005. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 52(2): 514-521.
9. Cuckle H. Biochemical screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol 2000: 97-101.
10. Cusick W, Rodis JF, Vintzileos AM, Albini SM, Macmahon M, Campbell WA. 1996. Predicting pregnancy outcome from the degree of maternal serum alpha-fetoprotein elevation. J Reprod Med 41: 327-332.
11. Davies BR, Casanueva E, Arroyo P. 1984. Placentas of small-for- dates infants: a small controlled series from Mexico City, Mexico. Am J Obstet Gynecol 149(7): 731 -736.
12. Simone N, Meroni PL, D'Asta M, et al. 2007a. Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphopholipid antibodies: a review of the literature. Ann NY Acad Sci 1108: 505-514.
13. Simone N, Meroni PL, D'Asta M, Di Nicuolo F, D'Alessio MC, Caruso A. 2007b. Pathogenic role of anti-beta-2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod update 13: 189-196.
14. Empson M, Lassere M, Craig J, Scott J. 2005. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 18(2): CD002859.
15. Ilaria C, Nebuloni M, Cetin I, et al. 2007. Complement activation in antiphospholipid syndrome: a clue for an inflammatory process? J Autoimmun 28: 160-164.
16. Kanfer A, Bruch JF, Nguyen G, et al. 1996. Increased placental antifibrinolytic potential and fibrin deposits in pregnancy-induced hypertension and preeclampsia. Lab Invest 74(1): 253-258.
17. Krause TG, Christens P, Wohlfahrt J, Lei U, Westergaard T. 2001. Second-trimester maternal serum alpha-foetoprotein and risk of adverse pregnancy outcome. Obstet Gynecol 97: 277-282.
18. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, et al. 1997. Outcome of planned pregnancies in systemic lupus erythematosus: a prospective study on 62 pregnancies. Br JRheumatol 36: 772-777.
19. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, Beaufils H, Lefebvre G, Piette JC. 2001. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis 60: 599-604.
20. Lim W, Crowther MA, Eikelboom JW. 2006. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295(9): 1050-1057.
21. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. 1996. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 14: 131-136.
22. Levine JS, Branch DW, Rauch J. 2002. The antiphospholipid syndrome. N Engl J Med 346(10): 752-763.
23. Maymon R, Cuckle H, Sehmi IK, Herman A, Sherman D. 2001. Maternal serum human chorionic gonadotrophin levels in systemic lupus erythematosus and antiphospholipid syndrome. Prenat Diagn 21: 143-145.
24. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. 1984. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 148(7): 886-894. Miyakis S, Lockshin MD, Atsumi T, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295-306.
25. Morssink LP, de Wolff BT, Kornman LH, Beekhuis JR, van der Hall TP, Manting A. 1996. The relation between serum markers in the second trimester and placental pathology. A study on extremely small for gestational age fetuses. Br J Obstet Gynaecol 103: 779-783.
26. Muller F, Dreux S, Sault C, et al. ABA Group. 2003. Very low alpha- fetoprotein in Down syndrome maternal serum screening. Prenat Diagn 23(7): 584-587.
27. Muller F, Ngo S, Aegerter P, et al. 1998. Evaluation of the Abbott system in maternal serum screening for Down syndrome: the AxSYM analyser, AFP and hCG reagents and Maciel Prenatal Interpretive Software. Clin Chim Acta 277: 65-75.
28. Newby D, Aitken DA, Crossley JA, Howatson A, Macri JN, Connor JM. 1997. Biochemichal markers of trisomy 21 and the pathophysiology of Down'syndrome pregnancy. Prenat Diagn 17: 941 -951.
29. Newby D, Dalgliesh G, Lyall F, Aitken DA. 2005. Alphafoetoprotein and alphafoetoprotein receptor expression in the normal human placenta at term. Placenta 26: 190-200.
30. Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM. 1997. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol 176(5): 1046-1051.
31. Petri M, Ho AC, Patel J, Demers D, Mehsen Joseph J, Goldman D. 1995. Elevation of maternal alpha-foetoprotein in systemic lupus erythematosus: a controlled study. J Rheumatol 22: 1365-1368.
32. Rand JH. 2007. The antiphospholipid syndrome. Hematology (Am Soc Hematol Educ Program) 2007: 136-142. Salmon JE, Girardi G. 2008. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 305: 51 -56.
33. Sebire NJ, Fox H, Backos M, Rai R, Paterson C, Regan L. 2002. Defective endovascular trophoblast invasion in primary antiphos- pholipid antibodysyndrome-associated early pregnancy failure. Hum Reprod 17: 1067-1071.
34. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. 2007. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 196: 167.e1-167.e5.
35. Silver RM, Draper ML, Byrne JL, Ashwood EA, Lyon JL, Branch DW. 1994. Unexplained elevations of maternal serum alpha-foetoprotein in women with antiphospholipid antibodies: a harbinger of fetal death. Obstet Gynecol 83: 150-155.
36. Smith GC, Wood AM, Pell JP, White IR, Crossley JA, Dobbie R. 2004. Second-trimester maternal serum levels of alpha-fetoprotein and the subsequent risk of sudden infant death syndrome. N Engl J Med 351(10): 978-986.
37. Spencer K. 2000. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 20: 652-656.
38. Tikkanen M, Hamalainen E, Nuutila M, Paavonen J, Ylikorkala O, Hiilesmaa V. 2007. Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption. Prenat Diagn 27: 240-243.
39. Wald NJ, George L, Smith D, et al. 1997b. Serum screening for Down's syndrome. Prenat Diagn 17: 821 -829.
40. Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler L. 1992. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. Br Med J 305: 391 -394.
41. Wald NJ, Kennard A, Hackshaw A, McGuire A. 1997a. Antenatal screening for Down'syndrome. J Med Screen 4: 181 -246.
42. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. 1996. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 88: 816-822.
43. Waller DK, Lustig LS, Cunningham GC, Golbus MS, Hook EB. 1991. Second-trimester maternal serum alpha-foetoprotein levels and the risk of subsequent fetal death. N Engl J Med 325: 6-10.
44. Wilson WA, Gharavi AE, Koike T, et al. 1999. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42: 1309-1311.